Additionally, we found that higher expression of CD133 was associated with poor differentiation (OR = 2.03, 95% CI: 1.32–3.14, p = 0.001) and lymph node metastasis (OR = 2.39, 95% CI: 1.62–3.52, p < 0.001) but there was no significant difference of CD133 expression between adenocarcinoma and squamous carcinoma (OR = 1.13, 95% CI: 0.93–1.38, p = 0.3) in NSCLC patients. This evidence concerns the gene PROM1 and non-small cell lung carcinoma.